Trial Profile
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SOTA-CKD3
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 01 Jun 2023 Results published in the Diabetes, Obesity and Metabolism
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 13 Jun 2020 According to a Lexicon Pharmaceuticals media release, results from this trial were presented at the virtual 80th American Diabetes Association (ADA) Scientific Sessions